TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A Being Patient interview with University of British Columbia researcher Cheryl Wellington discusses how cholesterol in the blood and brain may relate differently to neurological health. Wellington says higher LDL in midlife is associated with an estimated 7% to 9% increase in Alzheimer’s disease and related dementia risk, while key questions about causation and treatment effects remain.
Being Patient published an interview with Cheryl Wellington, a University of British Columbia researcher, about how cholesterol may affect brain health and Alzheimer’s risk. Wellington said high LDL cholesterol in midlife is associated with an estimated 7% to 9% higher risk of Alzheimer’s disease and related dementias, while emphasizing that cholesterol in the bloodstream and cholesterol inside the brain are distinct pools.
Wellington, a professor and vice chair of research in the University of British Columbia’s Department of Pathology and Laboratory Medicine, studies cholesterol and proteins that transport it, including ApoE. In the interview, she described the blood-brain barrier as limiting the movement of many substances between blood and brain. Cholesterol circulating in blood generally does not cross that barrier, she said, but it can still affect neurological health through blood vessels, while cholesterol produced and handled within the brain has its own roles.
Wellington linked elevated LDL with atherosclerotic plaque in blood vessels, which can affect blood flow and may occur alongside Alzheimer’s-related changes. She also discussed amyloid-beta, a protein naturally produced in the brain that is associated with Alzheimer’s disease. The interview describes the brain’s blood vessels and drainage pathways as part of how waste products, including amyloid-beta, leave the brain. Wellington said cholesterol-related processes may interfere with that clearance.
The discussion also covered cholesterol buildup in the brain’s immune cells and possible inflammation, with particular attention to people who carry the ApoE4 genetic variant. Wellington argued that lowering elevated LDL earlier in life may be more helpful than beginning treatment after symptoms appear. The source does not provide trial results demonstrating that cholesterol-lowering treatment prevents Alzheimer’s, and its risk estimate should be read as an attributed statement from the interview rather than a treatment-effect calculation.
How Midlife LDL May Affect Brain Risk
The discussion matters because cholesterol is a modifiable cardiovascular risk factor, and blood-vessel health is relevant to brain function as well as heart health. If higher LDL in midlife contributes to dementia risk, identifying and managing it could be part of broader efforts to protect long-term health. But the interview does not establish that lowering LDL will prevent Alzheimer’s or that cholesterol is the sole cause of the disease.
It also helps clarify why a single blood cholesterol result cannot be treated as a direct measure of cholesterol inside the brain. The proposed links involve separate pathways: effects on blood vessels and circulation, and processes within the brain involving immune cells, ApoE and amyloid-beta. Those distinctions matter when interpreting research or considering what a cholesterol test can tell someone about dementia risk.
Wellington’s remarks are not an individual risk assessment or a recommendation to start, stop or change medication. People with questions about LDL levels or treatment should discuss them with a qualified health professional, who can consider their overall health and established cardiovascular guidance.
Popular right now
De’Longhi Classic Matte Black Espresso Machine with Milk Frother
Bose QuietComfort Headphones (2nd Gen), Wireless Over-Ear Noise-Cancelling Headphones, Black
Breville Bambino Espresso Machine, Brushed Stainless Steel
As an affiliate, we earn on qualifying purchases.
Two Cholesterol Pools, Separate Pathways
The Being Patient item is a recorded interview with Wellington, conducted by the outlet’s founder, Deborah Kan. The publication says the live talk was produced with support from NewAmsterdam Pharma and that the sponsor had no role in choosing guests, shaping questions or reviewing the material before publication. That disclosure is relevant when evaluating the source and its funding.
In the interview, Wellington distinguished cholesterol circulating in the blood from cholesterol inside the brain, where the blood-brain barrier limits direct exchange. She also described two different kinds of plaque: atherosclerotic plaque in blood vessels and amyloid plaque associated with Alzheimer’s pathology. They are not the same material, though the interview discusses how vascular disease and Alzheimer’s-related changes can coexist.
The source frames the LDL-dementia connection around midlife exposure and cites an estimated 7% to 9% increased risk. It does not specify in the supplied text the underlying study, population, duration of follow-up or exact comparison group for that estimate. Those details are needed to interpret the figure precisely.
““Especially in people’s midlife years, high LDL increases the risk of Alzheimer’s disease and related dementias, estimated by about 7 to 9 percent.””
— Cheryl Wellington, University of British Columbia
Evidence Behind the Risk Estimate
The supplied interview does not identify the research used to calculate the 7% to 9% estimate, explain whether it refers to relative or absolute risk, or state the population and comparison level. Without those details, readers cannot translate the figure into an individual’s personal likelihood of developing dementia.
The interview presents possible mechanisms involving blood-vessel disease, amyloid-beta clearance, brain immune cells and ApoE4, but it does not establish that these processes prove a direct cause-and-effect relationship between LDL and Alzheimer’s disease. It also does not provide clinical trial evidence showing that lowering cholesterol prevents dementia or reverses existing disease.
The source does not specify which cholesterol-lowering approach, if any, produced the risk reduction Wellington referred to, nor the timing or size of that effect. The interview’s sponsor disclosure is available, but the supplied material does not include independent expert responses or a detailed review of the underlying evidence.
Research and Individual LDL Decisions
The next step for readers seeking to evaluate the claim is to consult the underlying studies and any later reporting that identifies their design, population and risk comparisons. Further research would need to clarify how much of the association reflects LDL itself, vascular health, other risk factors or a combination of pathways, and whether treatment initiated at particular ages changes dementia outcomes.
For now, the interview points to checking LDL and discussing results with a physician, rather than making a treatment decision based on Alzheimer’s risk alone. A clinician can weigh an individual’s cardiovascular profile and other health factors. The source does not announce a new trial, guideline or treatment, so no specific research milestone or policy change is established by this report.
Key Questions
Does high LDL cause Alzheimer’s disease?
The interview discusses an association between higher LDL in midlife and increased dementia risk, along with possible biological pathways. It does not establish that LDL alone causes Alzheimer’s disease.
Does cholesterol in the blood enter the brain?
Wellington said cholesterol in the bloodstream generally does not cross the blood-brain barrier. Blood cholesterol may still affect the brain through blood vessels, while cholesterol inside the brain is handled through distinct processes.
What does the 7% to 9% risk estimate mean?
It is an estimate Wellington gave for higher midlife LDL and Alzheimer’s disease or related dementias. The supplied source does not identify the study, comparison group or whether the figure is a relative or absolute increase, so it cannot be used to calculate an individual’s risk.
Can lowering cholesterol prevent dementia?
The interview suggests that lowering elevated LDL earlier may be beneficial, but the supplied material does not present trial evidence proving that cholesterol-lowering treatment prevents Alzheimer’s. Discuss cholesterol results and treatment questions with a qualified health professional.
What is ApoE4’s role in the discussion?
Wellington discussed possible cholesterol buildup and inflammation in brain immune cells, particularly among people who carry the ApoE4 variant. The interview does not quantify how much this pathway changes a person’s risk.
Source: beingpatient.com
